fingolimod
E518759
disease-modifying therapy
immunomodulatory drug
multiple sclerosis medication
small molecule drug
sphingosine 1-phosphate receptor modulator
Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
Statements (54)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
immunomodulatory drug ⓘ multiple sclerosis medication ⓘ small molecule drug ⓘ sphingosine 1-phosphate receptor modulator ⓘ |
| affectsCellType |
B lymphocytes
ⓘ
T lymphocytes NERFINISHED ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| contraindicatedIn |
certain types of heart block without pacemaker
ⓘ
recent myocardial infarction ⓘ stroke or TIA within 6 months ⓘ unstable angina ⓘ |
| developedBy | Novartis NERFINISHED ⓘ |
| hasAdverseEffect |
atrioventricular block
ⓘ
bradycardia ⓘ cough ⓘ diarrhea ⓘ elevated liver enzymes ⓘ headache ⓘ hypertension ⓘ lymphopenia ⓘ macular edema ⓘ |
| hasATCCode | L04AA27 ⓘ |
| hasBlackBoxWarning |
risk of bradycardia
ⓘ
risk of progressive multifocal leukoencephalopathy ⓘ risk of serious infections ⓘ |
| hasBrandName | Gilenya NERFINISHED ⓘ |
| hasCASNumber | 162359-56-0 ⓘ |
| hasDosageForm |
oral capsule
ⓘ
oral tablet ⓘ |
| hasFDAApprovalYear | 2010 ⓘ |
| hasGenericName | fingolimod ⓘ |
| hasINN | fingolimod NERFINISHED ⓘ |
| hasMechanismOfAction | sphingosine 1-phosphate receptor modulator ⓘ |
| hasMolecularFormula | C19H33NO2 ⓘ |
| hasPharmacologicalEffect |
lymphocyte sequestration in lymph nodes
ⓘ
reduction of circulating lymphocytes ⓘ |
| hasPregnancyRisk | teratogenic potential ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| isMetabolizedTo | fingolimod-phosphate ⓘ |
| isProdrug | true ⓘ |
| regulatesProcess | lymphocyte trafficking ⓘ |
| requiresMonitoring |
heart rate after first dose
ⓘ
liver function tests ⓘ ophthalmologic examination ⓘ |
| targetsReceptor |
S1P1 receptor
ⓘ
S1P3 receptor NERFINISHED ⓘ S1P4 receptor NERFINISHED ⓘ S1P5 receptor NERFINISHED ⓘ |
| therapeuticEffect |
delay of disability progression in multiple sclerosis
ⓘ
reduction of relapse rate in multiple sclerosis ⓘ |
| usedFor |
relapsing forms of multiple sclerosis
ⓘ
relapsing-remitting multiple sclerosis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.